Europe Circulating Tumor Cell (CTC) Diagnostics Market

The Europe circulating tumor cell (CTC) diagnostics market is expected to reach US$ 957.8 million by 2028 from US$ 508.0 million in 2021; it is estimated to grow at a CAGR of 9.5% from 2021 to 2028.

Due to advancements in technologies related to feasibility and processing times, circulating tumor cell diagnostics and liquid biopsy have recently gathered considerable interest as a noninvasive alternative to tissue biopsy in cancer patients. The implementation of liquid biopsy procedures is supported by a greater understanding of improved minimally invasive cancer detection technologies. The market growth will be influenced by the rising demand for noninvasive tools, and laboratory acceptance of CTCs tests and liquid biopsy. A liquid biopsy allows doctors to obtain information about tumors from a simple blood sample. A blood test is painless, noninvasive, cost-effective, and less time-consuming. In addition, CTCs, cfDNAs, exosomes, and microvesicles can be detected in a blood sample, making blood-based liquid biopsies more popular.

The COVID-19 emergency has encouraged the general population to try out digital services and scale up their usage, particularly to avoid having to visit a health center in person. The unprecedented impact of COVID-19 has been far-reaching, but the effects on cancer patients make them one of the worst affected groups. COVID-19 has profoundly impacted the number of patients undergoing cancer screening, diagnosis, and treatment. The increased pressure due to the growing rate of COVID-19 patients' hospitalization led to the re-profiling of many hospitals and departments, including oncology clinics, for accommodating the increasingly large number of COVID-19 patients. According to one study, many diagnostic and treatment procedures, including 2.3 million cancer surgeries, were canceled or postponed worldwide. Thus, the pandemic hindered the circulating tumor cell (CTC) diagnostics market growth.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the circulating tumor cell (CTC) diagnostics market. The Europe circulating tumor cell (CTC) diagnostics market is expected to grow at a good CAGR during the forecast period.

Europe Circulating Tumor Cell (CTC) Diagnostics Market Revenue and Forecast to 2028 (US$ Million)

Europe Circulating Tumor Cell (CTC) Diagnostics Market Segmentation         

By Technology

• CTC detection and Enrichment Method
• CTC Direct Detection Methods
• CTC Analysis

By Application

• Clinical/Liquid Biopsy
  • Risk Assessment
  • Screening and Monitoring
• Research
  • Cancer Stem Cell and Tumorigenesis Research
  • Drug/Therapy Development

By End-User

• Hospitals and Clinics
• Research and Academic Institutes
• Diagnostic Centers

By Country

• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Companies Mentioned

• Thermo Fisher Scientific Inc.
• Stemcell Technologies Inc.
• Qiagen
• Advanced Cell Diagnostics, Inc. (Bio-Techne Corporation)
• Screencell
• Ikonisys, Inc
• Fluxion Biosciences

Europe Circulating Tumor Cell (CTC) Diagnostics Strategic Insights

Strategic insights for the Europe Circulating Tumor Cell (CTC) Diagnostics provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Europe Circulating Tumor Cell (CTC) Diagnostics Report Scope

Europe Circulating Tumor Cell (CTC) Diagnostics Regional Insights

The geographic scope of the Europe Circulating Tumor Cell (CTC) Diagnostics refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.